About jade biosciences inc - JBIO
Jade Biosciences, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was founded by Benjamin T. Dake on July 27, 2018 and is headquartered in Waltham, MA.
JBIO At a Glance
Jade Biosciences, Inc.
Building 23
Waltham, Massachusetts 02453
| Phone | 1-617-443-2400 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -127,410,000.00 | |
| Sector | Health Technology | Employees | 55 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
JBIO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 2.288 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.308 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.005 |
JBIO Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -2,316,545.455 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
JBIO Liquidity
| Current Ratio | 21.091 |
| Quick Ratio | 21.091 |
| Cash Ratio | 20.325 |
JBIO Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -59.245 |
| Return on Equity | -62.31 |
| Return on Total Capital | -38.233 |
| Return on Invested Capital | -62.20 |
JBIO Capital Structure
| Total Debt to Total Equity | 0.218 |
| Total Debt to Total Capital | 0.217 |
| Total Debt to Total Assets | 0.207 |
| Long-Term Debt to Equity | 0.218 |
| Long-Term Debt to Total Capital | 0.217 |